Extent of Genital Infection With Cancer-Linked HPV May Relate to the Type of Immune Response

OncologyONCOLOGY Vol 11 No 3
Volume 11
Issue 3

A study of women with cervical intraepithelial neoplasia (CIN), a condition that often precedes invasive cervical cancer and is linked to infection with certain strains of human papillomavirus (HPV), found that those with the most extensive infections also

A study of women with cervical intraepithelial neoplasia (CIN), a conditionthat often precedes invasive cervical cancer and is linked to infectionwith certain strains of human papillomavirus (HPV), found that those withthe most extensive infections also had altered production of cytokines.The study is reported in the February 5th issue of the Journal of theNational Cancer Institute.

As Mario Clerici, md, Università degli Studi di Milano, Italy,and colleagues explain, several of the more than 23 strains of HPV areknown to be associated with the development of human cancers. Cervicalcancer, of which there are some 15,000 new cases in the United States eachyear, is one such malignancy.

Human papillomavirus-associated CIN is a frequent precursor of invasivecancer, say the authors, but it is also believed that host factors arecritical in regulating the growth of HPV-linked tumors. Certain cytokinesthat modulate immune function may be of particular importance, they add.According to the authors, the so-called type 1 cytokines interleukin-2(IL-2) and inter- feron-gamma (IFN-gamma) stimulate immune response andcan limit tumor growth; conversely, the type 2 cytokines interleukin-4(IL-4) and interleukin-10 (IL-10) inhibit immune response and can stimulatetumor growth.

Different Immunologic Profiles Correspond to Extent of Infection

In this study, Clerici and coworkers assessed the extent and type ofHPV infection in 30 women (median age, 34.5 years) diagnosed with CIN andin 10 healthy age-matched control subjects. In addition, they analyzedthe production of cytokines by peripheral blood mononuclear cells (PBMCs)extracted from blood samples provided by each woman.

Specifically, IL-2 production was measured in PBMCs exposed to solubleinfluenza antigen (to assess blood system-mediated immune response) orto a known stimulus of cell-mediated immune response, human leukocyte antigen(HLA) alloantigen. In addition, the researchers measured PBMC productionof IL-2, IFN-gamma, IL-4, and IL-10 following stimulation with the mitogenphytohemagglutinin, a substance known to induce the release of immune responsemediators by lymphocytes.

High-grade CIN associated with HPV infection was detected in all 30case patients, and cancer-associated HPV types 16 or 18 were detected inthe cervical tissue of 21 (70%) of the 30 women with CIN. Human papillomavirusinfection that had spread to other sites in the lower genital tract, resultingin more extensive disease, was detected in 16 (53%) of the 30 women withCIN; the remainder had HPV infection limited to the cervix.

Interleukin-2 production by PBMCs following stimulation with eitherinfluenza or HLA alloantigen was reduced in the group with extensive disease,as compared with those with local disease or the healthy control subjects.In contrast, IL-4 and IL-10 production in response to mitogen stimulationwas higher in the women with extensive disease than in the other two groups.The highest production of IL-4 and IL-10 was detected in patients withHPV infection extending beyond the genital tract.

Clerici and coworkers conclude that CIN is characterized by differentimmunologic profiles, corresponding to the extent of infection of the lowergenital tract. The study results suggest a pronounced shift from type 1to type 2 cytokine production, such that the production of type 1 cytokinesthat mainly enhance potentially protective cell-mediated immunity appearsto be defective in women with extensive HPV infection. These data reinforcethe need to analyze immune dysregulation in CIN patients and suggest thepossible usefulness of cytokine testing for assessing prognosis and decidingwhether cytokine-based therapy is indicated.

Role of Cytokines Merits Further Study

In an editorial accompanying this report, T.C. Wu, md, phd, and RobertJ. Kurman, md, The Johns Hopkins University, Baltimore, say that the studyby Clerici and colleagues adds to our growing understanding of the mechanismsby which the immune system mediates the behavior of HPV-associated cancers.Cytokine therapy, they believe, may have the potential to bolster diminishedimmune function associated with the progression of diseases influencedby inappropriate cytokine production. Wu and Kurman recommend further studiesto elucidate precisely how cytokine production is regulated in responseto HPV infection, as well as the role of cytokines in the critical stepbetween infection and tumor development.

Related Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Despite the addition of a TIGIT inhibitor to a checkpoint inhibitor resulting in high levels of safety, there is no future for that combination alone, according to Ritu Salani, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Following the results of the phase 3 CALLA trial, Jyoti S. Mayadev, MD, discusses the importance of global clinical multidisciplinary efforts in the locally advanced cervical cancer space.
Related Content